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Development of highly effective, broad-spectrum antiviral agents is the major objective
shared by the fields of virology and pharmaceutics. Antiviral drug development has
focused on targeting viral entry and replication, as well as modulating cellular defense
system. High throughput screening of molecules, genetic engineering of peptides, and
functional screening of agents have identified promising candidates for development
of optimal broad-spectrum antiviral agents to intervene in viral infection and control
viral epidemics. This review discusses current knowledge, prospective applications,
opportunities, and challenges in the development of broad-spectrum antiviral agents.
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The epidemic viral diseases of severe acute respiratory syndrome (SARS), Middle East respiratory
syndrome (MERS), Western/Eastern equine encephalitis (WEE/EEE), and Ebola, as well as
pandemic inﬂuenza A (H1N1) occurred in 2003, 2012, 2013, 2014, and 2009, respectively. The
emerging SARS, H1N1, and MERS, as well as re-emerging WEE/EEE and EBOVes are lethal and
transmissible through travelers. They have been identiﬁed as high priority biodefense pathogens
by the United States. The high virulence of these viruses and the absence of eﬀective therapies have
posed an ongoing threat to the public health. The conventional one-bug-one-drug paradigm is
insuﬃcient to address the challenge of emerging and re-emerging viral pathogens, and few drugs
are currently available to a prompt control of epidemic viral diseases (Chan et al., 2013; Raveh
et al., 2013; Carossino et al., 2014). Thus, it is imperative to develop a broad-spectrum class of
antiviral agents. Current strategies for the development of broad-spectrum antiviral agents focus
on two aspects of targeting viral infectivity and modulating host defense system, as discussed in
this review.
Agents Target on Viral Infectivity
Current strategies of controlling viral infectivity focus on identiﬁcation of agents capable of
intervening in the essential steps for viral infection, including viral attachment, fusion/endocytosis,
replication, assembly and budding in addition to drugs targeting viral envelope, as detailed in the
following subsections, and in Table 1 and Figure 1.
Abbreviations: AIV, avian inﬂuenza virus; ASLV, avian sarcoma leucosis virus; DENV, dengue virus; EBOV, Ebola virus;
EBV, Epstein-Barr virus; HAdV-2, human adenovirus type 2; HBV, hepatitis B virus; HCMV, human cytomegalo virus; HCV,
hepatitis C virus; HeV, Hendra virus; HIV, human immunodeﬁciency virus; HPV, human papillomavirus; HSV-1, herpes
simplex virus 1; IBV, infectious bronchitis virus; IFV-A, inﬂuenza virus Type A; IFV-B, inﬂuenza virus Type B; JEV, Japanese
encephalitis virus; JUNV, Junin arenavirus; LCMV, lymphocytic choriomeningitis virus; LFV, Lassa fever virus; MCMV,
murine cytomegalo virus; NDV, Newcastle disease virus; NiV, Nipah virus; PIV, parainﬂuenza virus; RSV, respiratory syncytial
virus; RVFV, Rift Valley fever virus; SARS-CoV, severe acute respiratory syndrome coronavirus; SeV, sendai virus; VACV,
vaccinia virus; VSV, vesicular stomatitis virus; WEEV, equine encephalitis virus; YFV, yellow fever virus.
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Viral Attachment
Viral attachment to host cells is a speciﬁc interaction between
viral surface proteins and host cell surface receptors and is
a critical step for most viral entry into cells. Thus, blocking
the interaction between viral particles and host cells is an
important task being seriously considered in development of
broad-spectrum antiviral agents to control viral infection, such
as IFV and HIV-1.
IFV-A infects host cells through interaction of its surface
antigen haemagglutinin with host cell surface receptor complex
containing sialic acid (Nicholls et al., 2008). The highly conserved
epitope at membrane-proximal stem of hemagglutinin has been
successfully targeted by the speciﬁc monoclonal antibody CR6261
to inhibit IFV-A infection via blocking the conformational
changes of haemagglutinins during viral attachment to host
cells. Pre- or post-treatment of mice with CR6261 eﬀectively
inhibit infection with various serotypes of IFV and protect
animals from IFV infection, demonstrating CR6261′s potential
for a broad-spectrum antiviral agent (Friesen et al., 2010). On
the other hand, the sialic acid of host cell surface receptor is
also a recognized target for development of broad-spectrum
antiviral agents. Sialidase hydrolyzes cell surface sialic acid
and prevents viral attachment to cells. DAS181, a sialidase
fusion protein consisting of a sialidase enzymatic domain
and an amphiregulin glycosaminoglycan binding sequence to
respiratory epithelium, has been shown to eﬃciently protect
mice from infection of various serotypes of IFV, such as
A/PR/8/34 (H1N1) and A/Victoria/3/75 (H3N2), as well as
PIV. Treatment of IFV-infected animals with DAS181 also
prevents pneumonia, indicating that DAS181 treatment prevents
animals from secondary bacterial infection (Hedlund et al.,
2010). Thus, CR6261 and DAS181 are candidates for developing
broad-spectrum antiviral agents to control infection by IFV
variants.
The HIV-1 particle carries only one envelope glycoprotein
precursor gp160, which can be cleaved by host proteases, such
as Furin, into gp120 and gp41; the resulting gp120 binds
to the cell surface receptor CD4 and coreceptors (CCR5,
CXCR4) for viral attachment and entry into cells (Wilen
et al., 2012). Three reagents silver, ovalbumin (OVA), and
lectin have been considered for development of broad-spectrum
antiviral agents; they are all cost-eﬃcient materials for antiviral
agent development. Silver is a common expedient for cooking
procedures and preserving water from contamination. Coating
nano-silver with polyvinylpyrrolidone (PVP) has been shown
to competitively bind to gp120, resulting in blocking viral
attachment to the host cell receptor CD4 and preventing viral
infection (Galdiero et al., 2011). In addition, PVP-coated nano-
silver exhibits antiviral ability to directly inhibit the infectivity
of viral particles in a cell-independent manner (Lara et al.,
2010). However, what other metal nanoparticles may interfere
with the infectivity of viral particles for developing broad-
spectrum antiviral agents remains to be investigated. Similarly,
OVA shows anti-viral ability, and 3-hydroxy phthalic anhydride-
modiﬁed OVA (HP-OVA) exhibits a broad-spectrum antiviral
activity by interfering with gp120 binding to CD4 (Li et al.,
2010). Many natural lectins, such as Concanavalin A and Lentil
lectin isolated from plants, have been shown to be cytotoxic,
to non-speciﬁcally activate T cells, and to agglutinate red blood
cells; these concerns have limited the use of lectins in antiviral
drug development (Barton et al., 2014). Mori’s group revealed
that the 12 kDa red algae lectin Griﬃthsin (GRFT) binds
N-glycan terminal mannose residues of gp120, blocks viral
binding to CD4-expressing cells, and inhibits HIV-1 entry into
cells in a glycosylation-dependent manner (Mori et al., 2005).
GRFT has been shown to possess a broad-spectrum antiviral
activity, and it is potentially safe in systemic treatment of
HIV-1 infection without inducing pro-inﬂammatory cytokines
(Mori et al., 2005; Barton et al., 2014). Cyanovirin-N (CV-
N), a natural lectin isolated from the cyanobacterium Nostoc
ellipsosporum, has been shown its high-aﬃnity to interact with
the N-linked high-mannose oligosaccharides of HIV gp120 and
block the ability of gp120 to mediate membrane fusion (Botos
and Wlodawer, 2003). However, the associated cytotoxicity and
immunogenicity have hindered the development of CV-N to
be a viable therapeutic agent. CV-N also inhibits EOBV and
HCV infection eﬀectively by interacting with viral envelope
glycoproteins at the early stages of viral entry (Barrientos
et al., 2004; Helle et al., 2006). Recently, (GGGGS)3, which is
a ﬂexible and hydrophilic linker, was used to conjugate with
CV-N to produce LCV-N; then PEG was used to modify the
N-terminus of LCV-N to produce PEGylated LCV-N (PEG-LCV-
N); and PEG-LCV-N is eﬀective to control IFN infection in
vivo (Wu et al., 2015). Accordingly, CV-N and its derivatives,
such as PEG-LCV-N, should be further developed and used as
broad-spectrum antiviral agents. Thus, PVP-coated nano-silver
particles, HP-OVA, GRFT, and CV-N should be further studied
for developing broad-spectrum antiviral agents to control HIV-1
infection.
Broad-spectrum neutralizing antibodies (bNAbs) are being
developed to target HIV gp120 for inhibition of HIV infection.
However, all the tested bNAbs were able to neutralize 10–50%
of HIV-1 isolates (Su and Moog, 2014). Recent development of
antiviral agents recognizes that two most conserved epitopes of
HIV-1 gp120 are CD4- and CCR5-binding sites (Gardner et al.,
2015). Fusion of CD4-Ig, which is a recombinant fusion protein
consisting of CD4 and Fc region, with a small CCR5-mimetic
sulfopeptide resulted in an eﬀective gp120-targeted agent eCD4-
Ig. eCD4-Ig has been shown to eﬀectively neutralize 100% of a
panel of HIV-1, HIV-2, and simian immunodeﬁciency viruses,
including bNAbs-resistant viral isolates (Gardner et al., 2015).
Accordingly, eCD4-Ig should be further developed as an antiviral
agent to control HIV infection.
Membrane Fusion and Endocytosis
Severe acute respiratory syndrome coronavirus, EBOV, HeV,
and NiV are highly pathogenic to a broad range of hosts
including human and various species of animals. The entry of
these viruses into host cells is dependent on cathepsin L (CatL),
which is a cellular lysosomal protease required for processing
gS-glycoprotein cleavage, to generate fusion of viral envelope
with cellular membrane after viral attachment (Pager and Dutch,
2005; Simmons et al., 2005; Pager et al., 2006; Kaletsky et al.,
2007). High throughput approaches have identiﬁed 50 molecules
Frontiers in Microbiology | www.frontiersin.org 2 May 2015 | Volume 6 | Article 517
Zhu et al. Broad-spectrum antiviral agents
from 5000-molecule libraries by their ability to inhibit CatL and
block viral entry into cells. The small molecule 5705213 and its
derivative 7402683 have been shown to eﬃciently inhibit CatL-
mediated cleavage of gS-glycoprotein and eﬀectively block SARS-
CoV entry into cells (Elshabrawy et al., 2014). The molecule
5705213 also blocks the entry of EBOV, HeV, and NiV into cells
via inhibition of glycoprotein cleavage (Elshabrawy et al., 2014).
Accordingly, identiﬁcation of small molecules to inhibit CatL is
a promising approach of developing broad-spectrum antiviral
agents to interfere with virus-cell membrane fusion, endocytosis,
and viral entry into cells.
Binding the gp120 of HIV-1 to cellular receptors triggers
a conformational change of the subunit gp41 for the fusion
of viral envelope and cellular membrane (Wilen et al., 2012).
The gp41 is a transmembrane protein, and the core of gp41
consists of three units of heptad repeat 1 (HR1) and three units
of HR2; HR2 units surround the HR1 units in an anti-parallel
manner to form a six-helix bundle structure. Conformational
changes of the six-helix bundle activate its function to mediate
the fusion of viral and cellular membranes together (Colman
and Lawrence, 2003). The HR2-mimicking peptide Enfuvirtide
(Fuzeon, a currently, clinically approved peptide fusion inhibitor)
can bind HR1 and interfere with conformational changes, thereby
blocking the formation of active six-helix bundle structure
(Eckert and Kim, 2001). Although Enfuvirtide is eﬀective in
control of wild-type HIV-1 and variants, Enfuvirtide treatment
results in resistant HIV-1 variants, which are also resistant
to reverse transcriptase inhibitors (such as Zidovudine) and
protease inhibitors (such as Ritonavir; Eckert and Kim, 2001).
Thus, development of next-generation inhibitors of HRs is
urgent. Recently, the P20, homologous to human troponin I
type 3 interacting kinase (TNNI3K)-like protein, is identiﬁed by
screening a DNA library of human bone marrow cells through
yeast two-hybridization method (Zhu et al., 2010). The P20
does not share any homology with Enfuvirtide, but it binds
to six-helix bundle and inhibit infection by various HIV-1
strains. It is reported that P20 variants with a common motif
(WGRLEGRRT) exhibit potent activity to inhibit HIV-1 infection
(Zhu et al., 2010); apparently, this common motif can be used
as a lead to develop optimal inhibitors for controlling HIV-1
infection.
Similar to HIV-1, a six-helix bundle structure is reported
to mediate the entry of class I enveloped viruses into host
cells, including coronavirus and paramyxovirus (Liu et al.,
2004; Wang et al., 2005); the six-helix bundle structure
appears to be an optimal target for developing broad-spectrum
antiviral agents. To achieve this end, the HR2 sequences
of the paramyxovirus NDV and the coronavirus IBV were
systemically analyzed. The primary structure of each helix
consists of heptad repeats containing seven commonly residues
(a–b–c–d–e–f–g)n. Replacement of the non-conservative sites
b, c, f, and g with the charged residues glutamic acid or
lysine followed by screening revealed a novel peptide AU
(VNKKIEEIDKKIEELNKKLEELEKKLEEVNKK) that is able to
completely inhibit single or double infection of cells with NDV
and IBV in vitro and in vivo (Wang et al., 2011). Furthermore,
tagging a cholesterol unit to the N-terminus of AU, resulting
in C-AU, not only prolongs the half-life of AU in vivo but also
increases its potency to control viral infection. For example,
intramuscular injection of chicken with C-AU one day prior to
virus inoculation and then every 3 days for three times after
viral inoculation resulted in a 70% protection of animals from
NDV infection (Li et al., 2013). This in vivo study demonstrated
feasibility of using antiviral peptides in clinical application to
control viral infection.
Viral Replication
RNA polymerase is essential for the replication of numerous
RNA viruses (te Velthuis, 2014). BCX4430, a novel nucleoside
analog, is an inhibitor speciﬁc for viral RNA polymerase
and exhibits broad-spectrum antiviral activity against viruses
including ﬁloviruses, ﬂaviviruses, arenaviruses, paramyxoviruses,
coronaviruses, and bunyaviruses (Warren et al., 2014). BCX4430
treatment completely protected golden hamsters from death
caused by infection with YFV (ﬂavivirus), and the treatment
also improved symptoms including weight loss and viremia.
BCX4430 also completely protected cynomolgus macaques from
infection with Marburg virus, a hemorrhagic fever virus of the
Filoviridae family, even it administered 48 h after viral infection
(Julander et al., 2014; Warren et al., 2014). Similarly, JMN3-003
can block the replication of various viruses (paramyxoviruses,
orthomyxoviruses, etc.) via speciﬁc inhibition of viral RNA
polymerases; interestingly, JMN3-003 treatment does not aﬀect
mRNA synthesis or protein translation of host cells (Krumm
et al., 2011). Both BCX4430 and JMN3-003 are able to
speciﬁcally target viral RNA polymerases without causing side
eﬀects to hosts. In addition, resistant viral variants were not
detectable in animals after treatment with BCX4430 or JMN3-
003 (Krumm et al., 2011; Warren et al., 2014). The pyrazine
derivative favipiravir (T-705) targets viral RNA-dependent RNA
polymerases, and T705 treatment inhibits almost all RNA viruses
without aﬀecting DNA or RNA synthesis of host cells. Clinically,
T-705 was reportedly eﬀective in controlling EBOV infection
(Oestereich et al., 2014; De Clercq, 2015). In addition, T-705
treatment of IFV-A-infected cells did not result in detectable
resistant variants (Mendenhall et al., 2011). Accordingly, agents,
targeting viral RNA polymerases, are optimal candidates of
broad-spectrum antiviral agents to be fully developed for the
control of RNA viruses.
Dihydroorotate dehydrogenase (DHODH) dehydrogenizes
dihydroorotate to orotic acid that is the key step of biosynthesis
of de novo pyrimidine to generate uracil essential for replication
of both viral RNA and DNA (Evans and Guy, 2004). Compound
A3, which was identiﬁed by high-throughput screening of 61,600
small-molecular-weight compounds, is able to target DHODH,
interrupt the biosynthesis of pyrimidine, and inhibit replication
of viruses including negative strand RNA viruses (such as IFV-
A and B), positive strand RNA viruses (such as hepatitis C
virus, HCV and DENV), and DNA viruses (such as VACV and
adenovirus; Hoﬀmann et al., 2011). Compound A3 treatment
also causes damages to viral genomic RNA and reduces viral
infectivity (Ortiz-Riano et al., 2014). Co-treatment with Ribavirin
enhances the therapeutic eﬃcacy of A3 in control of LCMV
(Ortiz-Riano et al., 2014). Ribavirin is a broad-spectrum antiviral
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agent and is approved for treatment of RSV and HCV infection
(Naik and Tyagi, 2012). Ribavirin, a guanosine analog, has been
used to inhibit synthesis of viral RNAs (Parker, 2005). Ribavirin
also inhibits RNA polymerase of HCV to interfere with viral
replication and induces formation of GTP analog RTP to cause
translational error of viral proteins (Cannon et al., 2009; Shah
et al., 2010). In addition, Ribavirin is known to inhibit replication
of RNA and DNA viruses via distinctive mechanisms and
replication of the same virus via distinct mechanisms in diﬀerent
cell types, depending on intracellular Ribavirin metabolism (Shah
et al., 2010). Interestingly, treatment with Ribavirin alone showed
a modest or no eﬀect on viral replication in HCV-infected
patients; however, combination with IFN dramatically improved
long-term antiviral response in patients (Dixit and Perelson,
2006). Another DHODH inhibitor, compound 1 (Cmp1), was
identiﬁed by the silico fragment-based drug design (FBDD);
Cmp1 inhibits both human and murine DHODH, in vitro, in a
dose-dependent manner (Konteatis, 2010). Cmp1, at low micro-
to nano-molar levels, is highly eﬀective in inhibiting replication
of human and murine cytomegaloviruses (HCMV and MCMV)
as well as HAdV-2 (Marschall et al., 2013). An in vivo study
showed that treatment of mice with Cmp1 at 30 mg/kg/day for
7 days resulted in a signiﬁcant suppression of MCMV replication
in various organs, including salivary gland, lung, liver, and spleen
(Marschall et al., 2013).
Antimycin A, isolated from Streptomyces kaviengensis,
displays a potent activity to control equine encephalitis viruses
(EEV) infection; treatment with antimycin A increased
survival rates of EEV-infected mice and reduced viral
replication (Raveh et al., 2013). Antimycin A is also able
to control infection by various RNA viruses, including
members of the Togaviridae, Flaviviridae, Bunyaviridae,
Picornaviridae, and Paramyxoviridae families (Raveh et al.,
2013). Interestingly, antimycin A inhibits cellular mitochondrial
electron transport chain and de novo pyrimidine synthesis,
indicating that host mitochondrial electron transport is a
viable target for identifying broad-spectrum antiviral agents.
The commercialized antiprotozoal agent Nitazoxanide has
been recently identiﬁed as a ﬁrst-in-class broad-spectrum
antiviral agent to inhibit the replication of various RNA and
DNA viruses, including HIV, IFV, DENV, HCV, HBV, and JEV
(Rossignol, 2014). Nitazoxanide is shown to mobilize Ca2+,
resulting in chronic sub-lethal stress of ER and disruption
of viral protein glycosylation and traﬃcking (Ashiru et al.,
2014).
Based on phylogenetic analysis, positive-sense RNA viruses
picornaviruses, caliciviruses, and coronaviruses are recognized as
members of picornavirus-like supercluster. These viruses possess
3C or 3C-like proteases (3Cpro or 3CLpro, respectively), which
contain a typical chymotrypsin-like fold and a catalytic triad (or
dyad) with a Cys residue as a nucleophile (Xia and Kang, 2011).
3Cpro and 3CLpro act as key enzymes for proteolytic processing
of viral polyproteins for virus replication (Wang and Liang,
2010). To target 3Cpro and 3CLpro of supercluster members,
the aldehyde GC373, the α-ketoamide GC375, and the bisulﬁte
adduct GC376, which share a common dipeptidyl residue, are
identiﬁed with the ability to inhibit the enzymatic activity of
3Cpro or 3CLpro via covalent binding to a nucleophilic Cys
residue in the conserved catalytic site of 3Cpro and 3CLpro
(Kim et al., 2012, 2013). GC373, GC375, and GC376 are being
developed as broad-spectrum antiviral agents to control viral
infection by picornavirus-like supercluster members.
Viral Assembly and Budding
Formation of viral ribonucleoprotein (vRNP) complexes,
consisting of viral RNA, RNA polymerase, and nucleoprotein,
is essential for the process in replication of negative-sense
single-stranded RNA viruses, such as IFV-A. After replication
of IFV genomic RNA in the nucleus, the vRNP complexes
translocate into cytoplasm for assembly of viral nucleocapsid
through a series of nuclear export pathways, such as the nuclear
export receptor chromosome region maintenance 1 (CRM1)-
mediated pathway (Mao and Yang, 2013). Leptomycin B (LMB)
is a highly speciﬁc inhibitor of CRM1, and LMB treatment
blocks the export of vRNP from nucleus to cytoplasm, thereby
suppressing the assembly of IFV-B particles (Dauber et al.,
2009). LMB has also been shown to inhibit replications of
DNA viruses, such as HSV-1 (Park et al., 2013). Although LMB
treatment was eﬀective, its toxicity was detectable in animals
(Perwitasari et al., 2014). Thus, LMB needs to be further studied
and modiﬁed to improve its therapeutic value in control of viral
infection.
The human CRM1 homolog exportin 1 (XPO1) mediates
transport of leucine-rich nuclear export signal-dependent cellular
protein and RNAs for cell growth and diﬀerentiation (Askjaer
et al., 1998). The nuclear export of vRNPs complexes is
mediated by the interaction of XPO1 with viral nuclear export
protein of IFV-A NS2 (Neumann et al., 2000). KPT-335
(also Verdinexor) is a small molecule antagonist of XPO1
(Perwitasari et al., 2014). In vitro studies showed that KPT-
335 is able to selectively and eﬀectively inhibit replication of
various IFV A and B strains, including pandemic H1N1, highly
pathogenic AIV H5N1, and the recently emerged H7N9. In vivo
studies showed that prophylactic and therapeutic administration
of KPT-335 protected mice from IFV A/California/04/09 or
IFV A/Philippines/2/82-X79, and KPT-335 treatment reduced
production of viral particles and proinﬂammatory cytokines in
lung with non-signiﬁcant toxicity (Perwitasari et al., 2014). Thus,
KPT-335 appears to be a promising broad-spectrum antiviral
agent.
It has been recently reported that enveloped viruses, such as
EBOV, utilize the cellular endosomal sorting complexes required
for transport (ESCRT) pathway to release their progenies from
infected cells; the ESCRT pathway is also the major escaping route
for enveloped viruses (Votteler and Schubert, 2008; Bucci, 2013;
Snyder et al., 2013; Dolnik et al., 2014). The tumor susceptibility
gene 101 product TSG101 is a subunit of ESCRT-I (Luyet et al.,
2008). The phenolic compound FGI-104 targets TSG101 and
inhibits viral budding of EBOV; treatment with FGI-104 at
10 mg/kg/day for 7 days protected mice from EBOV-caused
death. FGI-104 treatment also intervenes in HCV, HIV-1, IFV-
A, and HSV-1 infection via inhibition of TSG101 (Kinch et al.,
2009). Recently, Lu’s group reported that TSG101 serves as a
target of the Z protein PTAP-L domain of JUNV, which causes
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TABLE 1 | The antivirals target on viral infectivity.
Name Mechanism/Target position Derivation Target viruses Experiment Reference
CR6261 Act on the hemagglutinin Monoclonal antibody A serotypes of IFV-A In vivo Friesen et al. (2010)
DAS181 Hydrolyze cell surface receptor Sialidase fusion protein IFV-A and PIV In vivo Hedlund et al. (2010)
PVP-coated nanosilver Inhibit gp120 binding receptors Nano-silver
modification
HIV-1, etc. In vitro Lara et al. (2010)
HP-OVA Block glycoprotein- binding
receptors
Egg white protein
modification
HIV-1, etc In vitro Li et al. (2010)
GRFT Block glycoprotein- binding
receptors
Plant extract HIV-1, etc In vivo Barton et al. (2014)
CV-N Block gp120 to mediate fusion Extract from
cyanobacterium
HIV and EBOV, etc. In vitro Botos and Wlodawer
(2003)
eCD4-Ig Inactivate gp120 Recombinant HIV and SIV In vitro Gardner et al. (2015)
5705213 Block cathepsin cleavage Synthesis Broad-spectrum, e.g.,
SARS-CoV
In vitro Elshabrawy et al. (2014)
P20 Block six-helix bundle formation Synthesis Various HIV-1 strains In vitro Zhu et al. (2010)
C-AU Block six-helix bundle formation Recombinant protein NDV and IBV In vivo Wang et al. (2011)
BCX4430 Inhibit viral RNA polymerase Synthesis RNA viruses, e.g., YFV In vivo Warren et al. (2014)
JMN3-003 Inhibit viral RNA polymerase Synthesis Ortho- and para-myxoviruses In vitro Krumm et al. (2011)
T705 Target viral RNA polymerase Synthesis RNA viruses, e.g., EBOV In vivo De Clercq (2015)
A3 Interrupt biosymthesis of
pyrimidine
Synthesis Broad-spectrum, e.g., IFV-A
and B
In vitro Hoffmann et al. (2011)
Ribavirin Inhibit synthesis of viral RNA Synthesis RSV and HCV, etc In vivo Naik and Tyagi (2012)
(Review)
Cmp1 Anti-DHODH activity Synthesis broad-spectrum, e.g., HCMV In vivo Marschall et al. (2013)
antimycin A Inhibit the cellular mitochondrial
electron transport chain
Extract from
Streptomyces
RNA viruses, e.g., EEV In vivo Raveh et al. (2013)
Nitazoxanide Disrupt viral protein
glycosylation
Synthesis Broad-spectrum, e.g., HIV and
DENV
In vivo Rossignol (2014)
(Review)
GC373/375/376 Target 3C and 3CL proteases Synthesis Positive-sense RNA viruses,
e.g., SARS-CoV
In vitro Kim et al. (2012)
KPT-335 Nuclear export inhibitor Synthesis A serotypes of IFV-A In vivo Perwitasari et al. (2014)
FGI-104 Block hijacking TSG101 Synthesis Broad-spectrum, e.g., EBOV In vivo Kinch et al. (2009)
0013 Block viral protein interact with
cellular TSG101
Synthesis RNA viruses, e.g., JUNV In vitro Lu et al. (2014)
LJ001 Interrupt viral envelope Synthesis Enveloped viruses In vitro Wolf et al. (2010)
MP7-NH2 Inactivate virus Biosynthesis Enveloped viruses In vitro Sample et al. (2013)
Arbidol Block virus interact with cell
membrane
Synthesis Enveloped viruses, e.g., IFV-A In vivo Blaising et al. (2014)
(Review)
Argentine hemorrhagic fever, to facilitate viral budding (Lu et al.,
2014). Using the structure of TSG101-PTAP interaction site as
a target for silico screening of competitive binding molecules,
a novel compound 0013 was identiﬁed by its ability to block
the interaction of protein Z with TSG101 (Lu et al., 2014); the
0013 inhibited budding of JUNV particles. It is known that
PTAP L-domain-containing proteins are generally required for
separation of RNA viral particles from host cells (Chen and Lamb,
2008). Studies showed that the 0013 is eﬀective in inhibiting
PTAP-dependent budding of arenavirus, ﬁlovirus, and retrovirus
(Lu et al., 2014). Thus, compound 0013 can be used as a lead
compound for further development of broad-spectrum antiviral
agents to control viral budding.
Viral Envelope
Cells are able to promptly repair damages, ranging from 0.2
to 10 μm, of cell membrane by cytoplasmic endomembrane;
however, viral particles are incapable of repairing damaged viral
envelope (McMahon and Gallop, 2005). LJ001 is a type II
photosensitizer derived from aromatic methyl diene rhodanine
(Wolf et al., 2010). Treatment of cells with LJ001 results in
generating singlet oxygen (1O2) in the membrane bilayer, and
1O2-mediated lipid oxidation permanently changes biophysical
properties of viral envelope, resulting in interruption of virus-
cell fusion; in contrast, LJ001 treatment does not result in a
permanent damage of cell membrane due to the ability of cells
to repair lipid biosynthesis (Wolf et al., 2010). Thus, LJ001
treatment is able to irreversibly damage the viral envelope bilayer
structure, but not host cell membrane, to protect cells from fusion
with enveloped viruses, including bunyaviruses, ﬁloviruses,
poxviruses, arenaviruses, paramyxoviruses, ﬂaviviruses, IFV-A,
and HIV-1 in vitro (Wolf et al., 2010). Using LJ001 as a lead
compound, a new class of membrane-targeted photosensitizers
(i.e., oxazolidine-2,4-dithione derivatives: JL118 and JL122) has
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TABLE 2 | The antivirals based on host defense.
Name Mechanism/Target position Derivation Target viruses Experiment Reference
5′pppRNA RIG-I agonist From viral RNA
structures
IFV-A and VSV, etc In vivo Goulet et al. (2013)
ISG15 Distinctive mechanisms Knockdown RNA viruses, e.g., HIV-1 and
IFV-A
In vivo Morales and Lenschow
(2013) (Review)
ITIF Distinctive mechanisms Knockdown Broad-spectrum, e.g., HPV and
IFV-A
In vivo Diamond and Farzan (2013)
(Review)
IFITM Distinctive mechanisms Knockdown Enveloped viruses, e.g., IFV-A
and SARS-CoV
In vivo Diamond and Farzan (2013)
(Review)
C1 and C2 Rnase L activator Synthesis RNA viruses, e.g., PIV and VSV In vitro Thakur et al. (2007)
GSK983 Induce ISGs Synthesis HPV and EBV, etc In vivo Harvey et al. (2009)
Akt-IV P13k/Akt inhibitor Synthesis VSV and RSV, etc In vitro Dunn et al. (2009)
BEZ-235 PI3K inhibitor Synthesis LCMV and JUNV, etc In vitro Urata et al. (2012)
DRACOs Induce apoptosis Recombinant Broad-spectrum, e.g., IFV-A In vivo Rider et al. (2011)
Rapamycin mTOR pathway inhibitor Extract from
Streptomyces
Retroviruses, e.g., HIV-1 In vivo Nicoletti et al. (2011)
Baicalin Attenuate autophagy Extract from
Scutellariaradix
IFV-A and DENV, etc In vivo Zhu et al. (2015)
MG132 Proteasome inhibitor Synthesis Broad-spectrum, e.g., HIV-1
and IFV-A
In vitro Schubert et al. (2000)
Bortezomib Proteasome inhibitor Synthesis Broad-spectrum, e.g., IFV-A
and VSV
In vitro Dudek et al. (2010)
VL-01 Proteasome inhibitor Synthesis A serotypes of IFV-A In vivo Haasbach et al. (2011)
Mucin polymer Physical barrier from viruses Gastric mucus extracts Broad-spectrum, e.g., HPV and
IFV-A
In vitro Lieleg et al. (2012)
been developed to improve solubility and bioavailability for in
vivo application. In vitro studies showed that JL118 and JL122 are
able to increase 1O2 level 100-fold than LJ001 can do in cells. In
vivo studies showed that JL118 and JL122 treatment signiﬁcantly
delayed the death of RVFV (bunyaviruses)-infected mice (Vigant
et al., 2013).
Recently, mastoparan, which is a natural host defense peptide
(NHP) isolated from the invertebrate wasp, has been shown to
enter into viral envelop and interact with the lipid components
(Albiol Matanic and Castilla, 2004). The mastoparan-derived
peptide MP7-NH2 is able to alter the structure of viral
envelope and directly inactivate the infectivity of enveloped
viruses, including rhabdoviruses, ﬂaviviruses, herpesviruses, and
poxviruses, but not IFV-A (Sample et al., 2013). Possibly, IFV-
A envelope is less organized/ordered than the envelope of
viruses, such as VSV of rhabdoviruses, contributing to IFV
resistance to MP7-NH2 (Doms et al., 1988; Mukhopadhyay
et al., 2005; Harris et al., 2006). Pre-exposure of VSV particles
to MP7-NH2 signiﬁcantly reduced the infectivity of VSV in
vivo (Sample et al., 2013). Thus, LJ001 and MP7-NH2 should
be recognized as lead compounds for further development of
broad-spectrum agents to control viral infection by targeting viral
envelope.
The indole derivative Arbidol has been shown to block the
interaction between cell membrane and HCV glycoproteins
to inhibit viral entry and fusion into cells (Boriskin et al.,
2008). Arbidol also inhibits viral replication of HCV by
altering cytoplasmic proteins, which are essential for intracellular
traﬃcking (e.g., clathrin coat components, elements of the
cytoskeleton) and viral replication (e.g., membranous web),
and by hindering membrane rearrangements involved in viral
budding. Arbidol has been clinically shown to inhibit infection
by enveloped viruses, such as IFV-A and coronavirus, as well
as non-enveloped reovirus; thus, Arbidol is considered as a
broad-spectrum antiviral agent worthy of further development
(Blaising et al., 2014). Arbidol has been clinically used to treat
viral infections in Russia since 2005; however, it has not been
approved for use in Western countries (Blaising et al., 2014).
Summary for the First Section
In general, antiviral agents, such as DAS181 and C-AU,
which target viral attachment or virus-cell membrane
fusion/endocytosis are speciﬁc to viruses; however, their
treatments often result in drug-resistant viral variants, and their
speciﬁcity to viruses limits their potential for development of
broad-spectrum antiviral agents. Agents, such as BCX4430 and
JMN3-003, inhibit viral RNA polymerases and are non-cytotoxic;
their ability to block replication of various RNA viruses without
resulting in drug-resistant viral variants positions their candidacy
to be developed into optimal broad-spectrum agents to inhibit
RNA viruses. Compound A3, which interrupts biosynthesis of
pyrimidine in cells, appears to be a broad-spectrum antiviral
agent to control both RNA and DNA viruses; A3 treatment does
not result in drug-resistant viral variants. KPT-335, which blocks
viral assembly in cytoplasm, appears to be another promising
broad-spectrum antiviral agent to control RNA and DNA viruses.
FGI-104, which targets the cellular exporting ESCRT system,
inhibits viral budding without resulting in drug-resistant viral
variants. Although compound A3, KPT-335, and FGI-104, which
target on cellular machinery, are able to act as broad-spectrum
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FIGURE 1 | Schematic diagram of targets for broad-spectrum antiviral
agents. (a) Cathepsin L (b) gP120 (c) CD4 (d) six-helix bundle (e). N-glycan
terminal mannose residues (f) hemagglutinin (g) sialic acid (h) protein Z (i)
TSG101 (j) viral RNA polymerase (k) DHODH l. XPO1 → activate − l block. (1)
5705213 (2) PVP-coated nano-silver (3) HP-OVA (4) CV-N 5. eCD4Ig. (6) p20 (7)
Griffithsin (8) CR6261 (9) DAS181 (10) FGI-104 (11) Compound 0013 (12) VL-01
(13) Bortezomib (14) MG132 (15) JMN3-003 (16) BCX4430. (17) Compound A3
(18) Cmp1 (19) KPT-335 (20) Antimycin A (21) BEZ-235. (22) Akt-IV (23)
Rapamycin (24) DRACOs (25) 5′pppRNA (26) GSK983. (27) Compounds C1
and C2.
antiviral agents, their potential side eﬀects on patients need to be
addressed. Whether combination of these agents will be optimal
to control various viruses remains to be determined.
Agents Based on Host Defense
Host cellular defense is the ﬁrst hurdle against viral infection.
However, viruses are able to utilize cellular machineries for
viral replication. Growing knowledge has helped identify broad-
spectrum antiviral agents by targeting the cellular machineries of
defense, programmed cell death, and metabolism, as presented in
the following subsections, and in Table 2 and Figure 1.
Interferon (IFNs)
Type I IFNs [alpha and beta interferons (IFN-α/β)] are the ﬁrst-
line cytokines for host’s antiviral defense via immune system and
rapid induction of cellular modulators to inhibit viral replication
and spread (Burke et al., 2014). Viral infection yields highly
conserved pathogen-associated molecular patterns (PAMPs),
such as double-stranded RNA (dsRNA). Viral RNA contains
short hairpin dsRNA with triphosphorylated 5′ end (5′pppRNA)
that preferentially activates host’s pattern recognition receptors
(PRRs), such as retinoic acid inducible gene-I (RIG-I) and
related receptors (Ng and Gommerman, 2013). 5′pppRNA-
activated RIG-I interacts with mitochondrial antiviral-signaling
protein (MAVS) to result in activation of transcription factors,
such as IFN regulatory factor-3/7 (IRF-3/7), through the IKK-
related kinases TBK1 and IKKε, to induce IFN gene expression
(Schlee et al., 2009; Wilkins and Gale, 2010). An analog of
5′pppRNA, derived from the 5′ and 3′ untranslated regions of
VSV genome (Schlee et al., 2009), has been shown to induce
IFN expression andmultiple innate antiviral responses, including
IRF3/7, to control infections with IFV-A, DENV, VSV, HCV,
and VACV (Goulet et al., 2013; Olagnier et al., 2014). Mice,
treated with 5′pppRNA, fully recovered (100% survival) from a
lethal infection with H1N1 A/PR/8/34 IFV; 5′pppRNA treatment
completely inhibited viral replication in the lung (Goulet et al.,
2013).
Secretion of type I IFNs from virus-infected cells may trigger
antiviral activity in not only infected cells but also surrounding
uninfected cells in an autocrine- or a paracrine-dependent
manner. IFNs bind to cell surface IFN receptor (IFNAR) to
activate the Janus kinase signal transducer and activator of
transcription (JAK-STAT) pathway, leading to upregulation of
hundreds of IFN-stimulated gene (ISG) products, such as ISG15,
ITIT, IFITM and 2–5′ oligoadenylate synthetase (2-5A OAS;
Burke et al., 2014). In general, ISGs have been shown to exhibit
a wide range of antiviral abilities, including the ability to degrade
viral nucleic acids, to inhibit viral gene expression, and to serve as
PRRs to amplify IFN signals and elevate IFN expression (Bisbal
et al., 2001; Wilkins and Gale, 2010).
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ISG15 may act as an ubiquitin cross-reactive protein (Morales
and Lenschow, 2013). ISG15 is able to inhibit ubiquitination of
HIV-1 Gag protein and the interaction of Gag with TSG101,
which are important for releasing HIV-1 particles from cells
(Pincetic and Leis, 2009). ISG15 may block the ESCRT pathway
(see Viral Assembly and Budding) and disrupt cell release of
viral particles, such as HIV-1, EBOV, and ASLV (Morales and
Lenschow, 2013). ISG15 is also involved in ISGylation of viral
proteins that contributes to IFN-mediated inhibition of virus
replication. HERC5 is an IFN-induced E3 ubiquitin ligase for
ISG15 to mediate ISGylation of the IFV-A protein NS1 that
directly inhibits viral replication (Tang et al., 2010; Zhao et al.,
2010). ISG15 is also able to help other ISGs, such as IRF3.
ISGylation of IRF3 inhibits ubiquitination and degradation of
IRF3 (Lu et al., 2006). Stabilized IRF3 forms complex with
CREB binding protein (CBP) that translocates into the nucleus
and activates the transcription of IFNs and other ISGs genes
(Prinarakis et al., 2008). IRF3 has been shown to play a critical
role in the innate immune response against DNA and RNA
viruses. Overexpression of ISG15 resulted in increased antiviral
activity in vitro and in vivo, and knockdown of ISG15 resulted
in increased replication of VSV, SeV, and NDV in cells (Shi
et al., 2010) that further demonstrated the ISG15 antiviral
ability.
IFIT (Interferon induced proteins with tetratricopeptide
repeats) and IFITM (IFN-induced transmembrane protein) are
two families, involved in IFN activation, with distinctive genetics
and functions. Both IFIT and IFITM show broad-spectrum
antiviral activity to interfere with viral replication, transmission,
and virulence (Diamond and Farzan, 2013). Four human family
members (IFIT1, IFIT2, IFIT3, and IFIT5) and three rodent
family members (Iﬁt1, Iﬁt2, Iﬁt3) are identiﬁed. IFIT inhibits
viral infections through multiple mechanisms; IFIT1 and IFIT2
suppress the translation initiation (Hui et al., 2003), IFIT1 binds
uncapped or incompletely capped viral RNA (Pichlmair et al.,
2011) and sequesters viral protein (e.g., HPV E1) or RNA in
the cytoplasm (Terenzi et al., 2008). On the other hand, human
IFITM family composes of four members IFITM1, IFITM2,
IFITM3, and IFITM5; and murine IFITM composes of Iﬁtm1,
Iﬁtm2, Iﬁtm3, and Iﬁtm5. IFITMproteins traverse cell membrane
and are abundant in endosomes and lysosomes, and they can
prevent enveloped viruses from crossing endosomal or lysosomal
membranes and penetrating into the cytoplasm (Diamond and
Farzan, 2013). IFITMmembers also interfere with the membrane
fusion and endocytosis of viral particles to eﬀectively inhibit
viral infection by enveloped viruses; such as IFV, EBOV, SARS-
CoV and DENV (Brass et al., 2009; Huang et al., 2011). It is
shown that IFITM3 is able to limit IFV-A to the hemagglutinin
attachment phase of viral replication, contributing to control
of IFV-A infection in vivo (Brass et al., 2009; Feeley et al.,
2011). However, the detailed mechanisms for IFITMmembers in
diﬀerential inhibition of enveloped viruses and whether IFITM
may interfere with replication of non-enveloped viruses remain
to be studied.
The 2-5A OAS/RNase L pathway has been detected in various
types of mammalian cells (Bisbal et al., 2001). Upon activation by
viral dsRNA, 2-5A OAS synthesizes 2–5′ oligoadenylates (2-5A)
from ATPs. The resulting 2-5A binds to the inactive monomeric
form of RNase L to result in dimerization and activation of
RNase L, and activated RNase L mediates degradation of viral
RNA, contributing to IFN antiviral activity (Chakrabarti et al.,
2011; Silverman and Weiss, 2014). Thus, activators of RNase
L are considered for developing antiviral agents. However, 2-
5A is labile and cytotoxic; it may not be an optimal antiviral
agent candidate (Gale and Sen, 2009). High throughput screening
of the chemical library ChemBridge DIVERset of 30,000 small
molecules with the technique of ﬂuorescence resonance energy
transfer (FRET) has identiﬁed seven compounds eﬀective in
activating RNase L at micromolar concentrations (Thakur et al.,
2007). Two lead compounds, C1 and C2, are able to enter into
cells and induce RNase L activity without showing cytotoxicity.
Both C1 and C2 show broad-spectrum antiviral activity
against RNA viruses, including picornaviruses, rhabdoviruses,
paramyxoviruses, and retroviruses (Thakur et al., 2007). In
addition, GSK983, a novel tetrahydrocarbazole, has been shown
to induce signiﬁcant increases of seven ISGs, including ISG15,
ISG56, OAS1, OAS2, OASL, IL6, and TRAIL. GSK983 treatment
resulted in growth inhibition of cells infected by HPV, adenovirus
Ad-5, or EBV, possibly via induction of ISGs (Harvey et al., 2009).
However, the exact mechanism for GSK983 antiviral activity still
needs a clariﬁcation.
Programmed Cell Death
Apoptosis and autophagy are two major forms of programmed
cell death and play essential roles in not only homeostasis but
also survival in multicellular organisms (Lockshin and Zakeri,
2007; He and Klionsky, 2009). Apoptosis and autophagy are
distinguished on the basis of cell morphological changes (Hacker,
2000; Lockshin and Zakeri, 2007). Apoptosis is characterized
by activation of proteolytic caspases and formation of apoptotic
bodies that mediate degradation of cellular organelles. Autophagy
is characterized by the formation of autophagosomes to
sequestrate and transport cytoplasmic materials, including
damaged proteins and organelles, to lysosomes for degradation;
it is regarded as “self-eating” catabolism.
In response to viral infection, induction of apoptosis
may limit viral production and spread into adjacent cells,
while simultaneously promoting host innate and inﬂammatory
responses (Taylor et al., 2008; Upton and Chan, 2014).
However, viruses, such as HSV-1 and EBOV, are able to
escape from apoptotic control or reverse the process to
facilitate viral replication, respectively (Martins et al., 2012;
Fuentes-Gonzalez et al., 2013). Infection of viruses, such as
paramyxoviruses and orthomyxoviruses, may result in activation
of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway to
block apoptosis for the beneﬁt of viral replications (Sun et al.,
2008; Liu et al., 2010; Diehl and Schaal, 2013). Activated Akt
phosphorylates downstream transcription factors, such as FoxO1;
FoxO1 promotes degradation of IRF3 in suppression of cellular
antiviral response (see Programmed Cell Death; Lei et al., 2013).
The PI3K/Akt pathway inhibitor Akt-IV was identiﬁed by high
throughput screening of inhibitors of FoxO1 (Ramaswamy et al.,
1999; Sun et al., 2008). Akt-IV has been shown to inhibit
replication of the paramyxoviruses PIV5 and RSV. Interestingly,
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although the PI3k/Akt pathway is not involved in the replication
of VSV, Akt-IV is able to inhibit VSV replication (Sun et al., 2008;
Dunn et al., 2009). It has also been shown that the PI3K inhibitor
BEZ-235 is eﬀective in inhibiting the production of LCMV and
JUNV viral particles without causing cell toxicity (Urata et al.,
2012).
The dsRNA-activated caspase oligomerizer (DRACO) is a new
antiviral agent and is currently under preclinical studies. DRACO
consists of three components: a dsRNA recognition domain
derived from protein kinase R (PKR) for activating the defensive
IFN pathway, apoptotic protease activating factor-1 (Apaf-1) for
inducing apoptotic caspase pathways, and a transduction peptide
derived from HIV-1 TAT protein for entering into cells (Rider
et al., 2011). Thus, the DRACO approach induces both IFN and
apoptosis pathways for controlling virus-infected cells. Studies
showed that DRACO is able to induce death of cells infected
by either enveloped or non-enveloped viruses with undetectable
toxicity to uninfected cells (Rider et al., 2011). DRACO has been
reportedly to eﬀectively control infections by various viruses,
including orthomyxovirus, ﬂavivirus, picornavirus, arenavirus,
bunyavirus, reovirus, and adenovirus (Rider et al., 2011). Animal
studies showed that administration of DRACO from 1 day
prior to viral infection through 3 days post to viral infection
signiﬁcantly reduced production of viral particles and morbidity
of animals intranasally infected with IFVH1N1A/PR/8/34 (Rider
et al., 2011). DRACO appears to be an optimal broad-spectrum
antiviral agent for further development.
Autophagy is a basic cellular mechanism for degradation
of unnecessary or dysfunctional cellular components through
the actions of lysosomes to recycle cellular components (He
and Klionsky, 2009). Autophagy is reportedly involved in both
pro-survival and pro-death pathways depending on individual
cellular events (Nikoletopoulou et al., 2013). Autophagy has been
recognized to play roles in controlling intracellular pathogens
and fueling innate and adaptive immune responses to viral
infections (Liang et al., 1998; Nakashima et al., 2006; He and
Klionsky, 2009). Viruses, such as HSV-1 ICP34.5, can block
the formation of autolysosomes by targeting the autophagic
protein Beclin-1 to inhibit autophagy and allow viral replication
(Orvedahl et al., 2007). The non-structural protein 2C of foot-
and-mouth disease virus (FMDV) can interact with Beclin-1
for facilitating viral replication (Gladue et al., 2012). Viruses,
such as ﬂaviviruses, orthomyxoviruses, and coronaviruses, may
also utilize autophagic machinery to facilitate viral replication
(Prentice et al., 2004; Jackson et al., 2005; Zhou et al.,
2009; Heaton and Randall, 2011; Dumit and Dengjel, 2012).
Thus, whether autophagy is an optimal machinery targeted
for developing broad-spectrum antiviral agents remains to be
addressed. Treatment with the autophagy inhibitor Baicalin,
a natural product isolated from Scutellariaradix, resulted in
suppressing expression of autophagic Atg5–Atg12 complex and
autophagosomal marker LC3-II in cells (Zhu et al., 2015).
Baicalin treatment has been shown to suppress viral replication of
the ﬂavivirus DENV in vitro (Moghaddam et al., 2014). Baicalin
treatment also attenuated IFV-A-induced autophagy in cells and
eﬀectively increased survival rates of mice infected with IFV
H3N2 or H1N1 (Nayak et al., 2014; Zhu et al., 2015).
Mammalian target of rapamycin (mTOR) has been shown
to play roles in regulation of cell growth and autophagy in
response to changes of nutritional supplies, growth factors, and
stresses (Jung et al., 2010). ThemTOR is a serine/threonine kinase
and mediates signals to block autophagy via phosphorylation of
Atg13 and ULK1/2. Treatment of cells with the mTOR inhibitor
Rapamycin leads to dephosphorylation of ULK1/2 and Atg13,
resulting in induction of autophagy (Jung et al., 2010). HIV-1
infection may result in induction of mTOR for protein synthesis
that downregulates autophagy in lymphocytes and dendritic
cells, contributing to its blockage of host’s immune responses
(Zhou and Spector, 2008; Gougeon and Piacentini, 2009; van
der Vlist et al., 2011; Rehman et al., 2012). Treatment with
Rapamycin blocked HIV-1 infection of T cells in vitro (Roy
et al., 2002; Oswald-Richter et al., 2004) and inhibited HIV-1
infection of human leucocytes in SCIDmice (Nicoletti et al., 2009;
Nicoletti et al., 2011). Combination of Rapamycin with the viral
entry inhibitor Vicriviroc synergistically enhanced suppression
of HIV-1 infection in vitro (Heredia et al., 2008). Rapamycin
treatment has also been shown to reduce replication of avian
leukemia virus (ALV; Liu et al., 2013). These results suggested
that Rapamycin is a potential candidate for anti-HIV drug
development. However, how to adequately use agents to suppress
or activate autophagy for control of viral infection still needs to
be addressed.
Ubiquitin-Proteasome System (UPS)
Ubiquitination and ubiquitination-like modiﬁcations (e.g.,
SUMOylation) are widely involved in stability, localization,
and recycling of cellular proteins, as well as interactions of
proteins with their substrates (Hershko, 1983; Hochstrasser,
2009). Ubiquitination and ubiquitination-like modiﬁcations
play roles in regulation of cellular proteins for nuclear
transportation, proteolysis, translation, autophagy, and antiviral
responses. Ubiquitination is a post-translational modiﬁcation
via attachment of ubiquitin (UB) to a substrate protein. UB
is a small regulatory protein (MW 8.5 kDa) and found in
almost all eukaryotic cells. Ubiquitination is initially induced
by interaction of the UB-activating enzyme E1 to activate UB,
followed by interaction with the UB-conjugating enzyme E2
and the UB ligase E3 to form an isopeptide bond between
the carboxyl terminus of UB and the ε-amino group of lysine
residues on a targeted protein (Pickart, 2001). Subsequently, the
resulting UB-tagged protein binds to proteasome for degradation
and recycling. Accordingly, assembly of ubiquitination-
involved components and proteasomes together constructs the
UB-proteasome system (UPS; Coux et al., 1996).
Ubiquitination and ubiquitination-like modiﬁcations are
known to play important roles in regulation of viral components,
such as proteasomal degradation of HBV X protein (Kim et al.,
2008), HCV core protein (Shirakura et al., 2007), and HAV 3C
proteases (Schlax et al., 2007). It is logical to enhance the host
cell defense ability, via modulation of ubiquitin system, to control
viral infection. However, it has been reported that viruses are
able to utilize UPS to help viral replication (Isaacson and Ploegh,
2009). For example, HIV-1 and IFV-A and B utilize UPS to
modify their viral proteins HIV-Gag and IFV-M1, respectively,
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to facilitate viral replication. Ubiquitination of HIV-Gag, which
is a major structural protein, enhances its binding to TSG101
(subunit of ESCRT-I, see Viral Assembly and Budding) for
assembly of viral particles and completion of viral budding
and release (Pornillos et al., 2002; Klinger and Schubert,
2005). SUMOylation of IFV-A-M1 plays an important role
in modulating assembly of viral particles (Pal et al., 2011;
Rossman and Lamb, 2011; Wu et al., 2011). Viruses are also
able to utilize UPS to subvert or interfere with host innate
defense system (such as APOBEC3G and NF-kB). The HIV-
1 proteins Vif, Nef, Vpu, and Vpr, are essential for viral
replication, and they are important for evading host immune
system (Strebel, 2013). For example, the unique zinc-ﬁnger
motif of Vif recruits E3 ubiquitin ligase to form a complex
of CBF-β-CUL5-ELOB-ELOC, which ubiquitinates the human
antiviral protein APOBEC3G for degradation (Huthoﬀ and
Towers, 2008; Guo et al., 2014). NF-kB is sequestered by IkB
in the cytoplasm; viral infection, such as HIV-1 and EBV,
may result in the activation of NF-kB through UPS-dependent
degradation of IkB, leading to up-regulation of a variety of
antiviral genes (Magnani et al., 2000; Mingyan et al., 2009; Sun
and Cesarman, 2011). However, IFV-A is able to utilize NF-
kB-dependent signaling pathways, via degradation of IkB to
activate NF-kB, for viral replication (Ludwig and Planz, 2008).
It has been reported that the proteasome inhibitors MG-132
(Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal, peptide aldehyde),
Lactacystin, and Bortezomib are able to block NF-kB activation,
via inhibition of IkB degradation (Omura et al., 1991; Palombella
et al., 1994; Hideshima et al., 2009). MG132 treatment inhibits
IFV-A replication (Widjaja et al., 2010). Treatment of cells
with Bortezomib (PS-341), at non-cytotoxic levels, signiﬁcantly
reduces IFV-A and VSV replication (Dudek et al., 2010). The
proteasome inhibitor VL-01 is able reduce viral replication
of three IFV strains, including A/Puerto Rico/8/34 (H1N1),
A/Regensburg/D6/09 (H1N1v) and A/Mallard/Bavaria/1/2006
(H5N1). Treatment of IFV-infected mice with VL-01 resulted in
reducing viral replication in the lung and increasing mice survival
without any side eﬀects (Haasbach et al., 2011).
Paramyxoviruses (SeV and RSV) may induce ubiquitination
of STATs to evade host IFN response [see Interferon (IFNs)];
the SeV C protein and the RSV NS protein are able to induce
ubiquitination of STAT1 and STAT2, respectively, for degradation
(Garcin et al., 2002; Elliott et al., 2007). Treatment of SeV-
or RSV-infected cells with MG132 reduced viral replication
in a dose-dependent manner (Watanabe et al., 2005; Lupfer
and Pastey, 2010). More than ten families of viruses utilize
UPS to complete their replication for a successful infection
(Calistri et al., 2014). Treatment with MG-132 or Lactacystin
eﬀectively blocks maturation, budding, and infectivity of HIV-
1 particles (Schubert et al., 2000; Klinger and Schubert, 2005;
Votteler and Schubert, 2008). Proteasome inhibitors have also
been shown to interfere with replication of herpesviruses
(Delboy et al., 2008), coronaviruses (Yu and Lai, 2005), and
rotaviruses (López et al., 2011). Thus, it is promising to
develop optimal broad-spectrum non-cytotoxic antiviral agents
by inhibiting UPS.
Native Barrier
Mucus plays an important role in protection of epithelial cells
from invading pathogens in the respiratory, gastrointestinal,
urogenital, visual, and auditory systems of animals (Thornton
and Sheehan, 2004; Martinez et al., 2015). Mucins, the major
components of mucus, are a family of high molecular weight
glycoproteins (up to hundreds of kDa) produced by epithelial
tissues in both vertebrates and invertebrates. Mucins are able
to form a gel-like barrier to protect cells from viral attachment
(Lieleg et al., 2012). Porcine mucins, isolated from gastric mucous
epithelium, has been shown to form a shield to trap viral particles,
such as HPV and IFV IFV-A with sizes of ∼50 and∼100 nm,
respectively (Buck et al., 2005), as well as HIV (∼120 nm) and
HSV (∼180 nm; Lai et al., 2010; Lieleg et al., 2012). Porcine gastric
mucins may be used as antiviral agents for future biomedical
applications.
Summary for the Second Section
More than 200 cellular functional proteins are directly and
indirectly involved in replication of HIV-1 (Brass et al., 2008;
Dziuba et al., 2012). Understanding the roles of cellular proteins,
and associated pathways, in viral replication has helped design
new strategies for developing broad-spectrum antiviral agents,
such as the PI3K inhibitor Akt-IV and BEZ-235, the mTOR
inhibitor Rapamycin, and the proteasome inhibitors MG132 and
VL-01. Eventually, each agent has its own speciﬁcity to intervene
in replication of targeted viruses. However, challenges of drug
toxicity to hosts and generation of resistant viral progenies
remain to be addressed.
Conclusion and Perspectives
Current development of broad-spectrum antiviral agents
targeting viral infectivity and modulating host defense system has
substantially advanced the ﬁelds of virology and pharmaceutics
and signiﬁcantly contributed to the health care of human
and animals. However, there are concerns of viral resistance
associated with agents targeting viral components and non-
speciﬁc side eﬀects associated with agents targeting cellular
machineries. Accordingly, how to reduce viral resistance and
increase drug speciﬁcity are current challenges to be addressed.
Whether combined uses of agents to target both viral components
and cellular machineries may improve antiviral eﬃcacy, reduce
viral resistance, and minimize toxicity in the control of viral
infection and epidemic viral diseases needs to be clariﬁed.
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